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SUMMARY – Prostate cancer is one of the most important men’s health issues in developed 
countries. For patients with prostate cancer a preoperative staging of the disease must be made. In-
volvement of lymph nodes could be assessed using imaging methods (CT or/and MRI), however, 
newer methods also exist (PET/CT, PSMA PET/CT). For some patients during radical prostatec-
tomy a pelvic lymphadenectomy is recommended. Pelvic lymphadenectomy is indicated in intermedi-
ate- and high-risk group patients and with increased probability of lymph node invasion. The most 
used prediction tools for preoperative assessment of lymph nodes are Briganti and MSKCC nomo-
grams and Partin tables. Pelvic lymphadenectomy can include different lymph nodes group, but 
 extended lymphadenectomy is the recommended procedure. In 1-20% of patients, the lymph node 
invasion is present. Pelvic lymphadenectomy is primarily a diagnostic and staging method, and in 
minority of patients with positive lymph nodes it can be a curative method, too. In other patients with 
positive lymph nodes adjuvant therapy (radiotherapy and androgen deprivation therapy) can be 
 beneficial.
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Introduction
Prostate cancer (PCa) is one of the men’s leading 
health issues, especially in the more developed coun-
tries. These is a consequence of its high incidence, dif-
ferent types of therapy which are usually prolonged 
over time with regularly check-up and substantial 
mortality. PCa is the second most commonly diag-
nosed cancer in men, with an estimated 1.1 million 
diagnoses worldwide in 2012, accounting for 15% of 
all cancers diagnosed1. It is also the fifth cause of can-
cer death. The frequency of autopsy-detected PCa is 
roughly the same worldwide and increases from 5% in 
men below 30 years to 59% with age >79 years2,3. The 
incidence of PCa varies widely between different geo-
graphical areas. The highest incidence was noticed in 
Norway (129.7/100.000) and Sweden, compared to 
lowest rates in Bangladesh, Nepal and Bhutan1. Com-
pared to other European countries, Croatia has an in-
termediate incidence rate of 64.8/100.000 in the 2014 
with the cumulative incidence rate (0-74 years) of 5%4. 
As the incidence, mortality from PCa is also different 
between regions. The age-standardized mortality rate 
for Croatia in 2014 was 54.9/100.000 and assigned 
our country among top ten EU countries in prostate 
cancer mortality4.
Incidence of PCa is mainly dependent on age. 
Family history and racial/ethnic background are asso-
ciated with an increased PCa incidence which suggests 
genetic predisposition5,6. A variety of exogenous/envi-
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ronmental factors (metabolic syndrome, diabetes, cho-
lesterol, obesity, dietary factors, hormonally active 
medications as 5-alpha-reductase inhibitors and tes-
tosterone) may have impact on PCa incidence and the 
risk of progression7-15.
Staging of prostate cancer
After the establishing diagnosis of PCa a proper 
clinical staging of the disease must be made. This stag-
ing includes tumor relationship with prostate and sur-
rounded organs (T stage), status of lymph nodes (N 
stage) and presence of distant metastases (M stage).
T staging historically included transrectal ultra-
sound (TRUS). TRUS and derived techniques (3D-
TRUS, colour Doppler) cannot differentiate between 
T2 and T3 tumors with adequate accuracy and cannot 
be recommended for the staging15-18. Modern imaging 
techniques as computed tomography (CT) and mag-
netic resonance imaging (MRI) are currently preferred 
diagnostic methods. Multiparametric magnetic reso-
nance imaging (mp-MRI) with 1.5 Tesla or 3 Tesla is 
currently the best modality for local staging of the dis-
ease15,19-21. But because of its low sensitivity for focal 
(microscopic) extraprostatic extension, mp-MRI is 
still not recommended for local staging in low-risk pa-
tients15,20,22,23.
N staging in PCa patients was evaluated using CT, 
MRI, choline PET/CT and prostate specific mem-
brane antigen-based PET/CT15.
M staging is determined using bone scan, fluoride 
PET/CT, choline PET/CT, MRI and prostate-specif-
ic membrane antigen-based PET/CT15.
Preoperative assessment of the lymph nodes
Different diagnostic modalities are included to es-
tablish preoperative status of lymph nodes. Preopera-
tive assessment of lymph nodes standardly includes 
abdominopelvic CT scan or T1-T2-weighted MRI 
(Fig. 1). These methods indirectly assess nodal inva-
sion using lymph nodes diameter and morphology. 
Generally, the pelvic lymph nodes with a short axis > 8 
mm and >10 mm outside pelvis are considered posi-
tive, e.g. malignant15. Meta-analysis of diagnostic ac-
curacy of CT and MRI in the staging of pelvic lymph 
nodes in PCa patients which included 24 studies 
showed sensitivity of 42% and specificity of 82% for 
CT and 39% sensitivity and 82% specificity for MRI24. 
Analysis of EUREKA database showed that CT has a 
sensitivity of 8.8% and specificity of 98% in predicting 
lymph nodes involvement with significant association 
only with high-risk subgroup with a sensitivity of 
11.8% and positive predictive value of 44.4%25. Ac-
cording to previous data the role of CT and conven-
tional MRI in prediction of lymph node involvement 
is still limited and must be combined with clinical pre-
dictive nomograms.
Detection of microscopic lymph node involvement 
using CT is < 1% in patients with ISUP < 4 cancer, 
PSA<20 ng/ml or localized disease15. Diffusion-
weighted MRI has a potential to improve preoperative 
detection of positive lymph nodes. This modality en-
ables detection of metastases in normal-sized lymph 
nodes in 64-79% of patients with prostate or bladder 
cancer (21 and 26 of 33 patients with positive lymph 
nodes); these positive lymph nodes would be missed 
with conventional MRI or CT26.
The meta-analysis of 609 patients showed that 
choline PET/CT has a sensitivity of 62% and specific-
ity of 92% for detection of lymph node involvement27. 
Other studies showed that the sensitivity of choline 
PET/CT increased from 8.2% in intermediate risk to 
Fig. 1. Selected image from contrast enhanced computed 
tomography imaging in 70-year old male patient with 
biopsy proven prostate cancer demonstrated an enlarged 
left external iliac lymph node (white arrow). The size and 
irregular margins of the node are highly suspicious for a 
lymph node metastasis
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50% (high risk) and 71% (very high risk)27-29. Due to 
its relatively low sensitivity choline PET/CT is not in-
cluded in routinely assessment of lymph node involve-
ment15.
Prostate-specific membrane antigen-based PET/
CT (PSMA PET/CT) is a promising technique for 
detection of lymph node involvement15. PSMA is usu-
ally labelled with 68Ga or 18F as a tracer. This technique 
has a sensitivity and specificity of 80%30.
Prostate cancer – the risk groups
The preoperative different diagnostic modalities 
must be used according to different risk group affilia-
tion of the patient. The most frequently used are EAU 
risk group classification (essentially based on D’Amico 
classification system for PCa) and International Soci-
ety of Urological Pathology 2014 grades (Table 1 and 
2)15. EAU guidelines for prostate cancer recommend-
ed that in the patients with low-risk localized disease 
additional imaging modalities are not needed. Patients 
with intermediate-risk and ISUP grade > 3 and with 
high-risk localized disease/locally advanced disease 
should perform cross-sectional abdominopelvic imag-
ing and bone scan for metastatic screening15.
Radical prostatectomy  
and pelvic lymphadenectomy
Radical prostatectomy (RP) is one of the therapy 
options for patients with PCa with the main goal of 
cancer removal. In some patients the pelvic lymph 
node dissection (PLND) is also needed. The EUA 
guidelines about prostate cancer recommended per-
forming extended PLND in intermediate- and high-
risk group patients when the estimated risk for posi-
tive lymph nodes exceeds 5%15. PLND is indicated 
only in selected patients with a higher risk for lymph 
node invasion (LNI) because this procedure is associ-
ated with prolonged operative time and increased risk 
of complications15,31.
Prediction of lymph node invasion  
among patients undergoing radical prostatectomy
One of the very important issues of PCa patients is 
preoperative prediction of lymph node invasion (LNI). 
Depending on this prediction the need for pelvic 
lymphadenectomy is determined. The three most used 
nomograms for predicting positive lymph nodes in 
PCa patients are Briganti, Partin and Memorial Sloan 
Kettering Cancer Center (MSKCC) nomograms15.
Initially, Briganti nomogram is based on routinely 
available clinical variable (clinical stage, PSA and bi-
opsy Gleason sum) (Fig. 2)32. Later the nomogram is 
strengthened by the inclusion of percentage of positive 
cores as a covariate (Fig. 3)33. Using the nomogram 
cut-off of 5% the sensitivity was 87.8%, specificity 
70.3% and negative predictive value 98.4%32. Using 
this updated nomogram with cut-off of 5%, 385 of 588 
patients (65.5%) would be spared from ePLND, and 
LNI would be missed in only 6 patients (1.5%). All 
these six patients had two or fewer positive lymph 
nodes33.




PSA < 10 ng/mL
and GS<7 (ISUP grade 1)
and cT1-2a
PSA 10-20 ng/mL
or GS 7 (ISUP grade 2/3)
or cT2b
PSA > 20 ng/mL
or GS > 7 (ISUP grade 4/5)
or cT2c
any PSA
any GS (any ISUP)
cT3-4 or cN+
Localized Locally advanced
GS = Gleason score; ISUP = International Society for Urological Pathology; PSA = prostate-specific antigen
Table 2. International Society of Urological Pathology 
(ISUP) 2014 grades
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Recently, the new Briganti nomogram (2017) in-
cluded more prostate biopsy details including biopsy 
Gleason grade group, percentage of cores with high-
est-grade PCa, and percentage of cores with lower-
grade disease is developed34. Using a cut-off of 7% this 
nomogram can help to significantly reduce the num-
ber of unnecessary PLND with a risk of missing only 
1.5% of patients with LNI34. Since the number of in-
clusion data needed for using this nomogram has in-
creased, its clinical value as a routine tool is doubtful.
Also, a novel model for LNI risk assessment is de-
veloped for men diagnosed with PCa via MRI-target-
ed biopsies. This model includes PSA, clinical stage 
and maximum diameter of the index lesion on mp-
MRI, grade group on targeted biopsy, and the presence 
of clinically significant PCa on concomitant system-
atic biopsy35.
Memorial Sloan Kettering Cancer Center 
(MSKCC) nomogram includes analysis of patients age, 
PSA, primary and secondary Gleason number, clinical 
tumor stage, number of positive biopsy cores and calcu-
lated probability of lymph node involvement36.
Partin tables make prediction of pathological stage 
based on clinical stage, serum prostate‐specific antigen 
and biopsy Gleason score37.
The comparison between these three nomograms 
showed that their accuracy is similar without signifi-
cant advantages of each one38. But, in Europe and 
Croatia the most frequently used nomogram is still 
Briganti from 2012. All these nomograms can be 
found on the Internet or downloaded as mobile phone 
applications, what facilitates their use in everyday 
practice.
Extent of pelvic lymph node dissection
PLND is primarily a staging procedure for detec-
tion of nodal metastases in PCa patients and in some 
patients potentially could be a curative procedure15. 
The presence of lymph node metastases is one of the 
strongest prognostic factors of poor oncologic out-
come15,39. Anatomic definitions of PLND distinguish 
limited, standard, extended and super-extended PLND 
(Fig. 4)40. Limited PLND includes removal of lymph 
nodes in obturator fossa and standard PLND includes 
lymph nodes around external iliac vessels and in obtu-
rator fossa. Extended PLND (ePLND) includes bilat-
eral dissection of the right and left common iliac ves-
sels (up to the ureteral crossing), internal iliac vessels, 
external iliac vessels and obturator fossa. Super-ex-
tended include all nodes as extended plus all common 
iliac, presacral nodes and even some authors include 
cranially positioned lymph nodes (paraaortic and para-
caval)40-42.
Incidence of positive lymph nodes  
at radical prostatectomy
The incidence of positive lymph nodes (Fig. 5) at 
radical prostatectomy varies as an operative technique 
and the extent of lymph node dissection changes dur-
ing time. In the beginning, when the lymphadenecto-
Fig. 2. Briganti nomogram (2006) predicts  
the probability of lymph node invasion based  
on pre-treatment PSA, clinical stage and biopsy  
Gleason sum; adapted from (32)
Fig. 3. Updated Briganti nomogram (2012)  
with the inclusion of percentage of positive cores  
as a covariate; adapted from (33)
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my included only obturator lymph nodes the incidence 
of positive lymph nodes was around 1-3%43. Recently, 
the extended lymphadenectomy has become a stan-
dard procedure and incidence of positive lymph nodes 
increased up to 10%33,44. Probably the largest single in-
stitution study from Mayo Clinic included 19 946 
men treated with RP and 1011 (5.1%) of them had 
positive lymph nodes45. Men with positive lymph 
nodes had a higher PSA, higher clinical T stage, high-
er pathological T stage, higher Gleason score and 
higher rate of positive margin compared to lymph 
node negative patients45.
Overall, LNI can be found in 1.1-26% of patients 
undergoing PLND32,46-48. Such variability of the posi-
tive lymph nodes relates to clinical characteristics of 
PCa at diagnosis as well as to extent of PLND. Few 
authors proved that extended PLND (ePLND) is as-
sociated with the higher lymph node detection rate 
compared to limited PLND, regardless of PCa agres-
siveness32,49-52. For this reason, whenever PLND is in-
dicated it must be performed as ePLND15,53. Standard 
or limited PLND must be omitted due to high rates of 
false-negative findings15.
In patients undergoing ePLND, LNI is detected in 
5-6%, 20-25% and 30-40% related to low-, intermedi-
ate-, and high-risk PCa52. Consequently, EAU guidelines 
recommended ePLND for lymph node staging during 
RP in patients with intermediate- and high-risk PCa, 
and this can be abandoned in low-risk PCa patients15.
The influence of PLND on biochemical  
and clinical recurrence, cancer-specific  
and overall mortality
Most studies which compared biochemical and cli-
nical recurrence, cancer-specific and overall mortality 
after PLND or noPLND did not find any difference 
between these two groups40. Also, comparison between 
different type of PLND did not show any difference in 
the abovementioned variables31,40,54,55-67. These studies 
strongly support that PLND is primarily staging pro-
cedure.
The influence of PLND on surgical  
complications and functional outcomes
Extended PLND is associated with increased op-
erative time, intraoperative complications, bleeding 
and hospital stay40,68. Also, extended PLND prolonged 
operative time for about 30 minutes compared to lim-
ited PLND and increased development of lympho-
cele40,69. Other studies did not find any difference in 
complications rate between different lymphadenecto-
my approach40,70,71.
Functional outcomes after radical prostatectomy 
included assessment of urinary continence and erectile 
function. In a study of almost 1000 patients neither 
limited nor extended PLND did not have additional 
negative impact regarding urinary continence and 
Fig. 4. Anatomical classification of pelvic lymph nodes
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erectile function recovery72. Only patient age at sur-
gery, preoperative erectile function and pathological 
tumor stage represent predictors of erectile function 
recovery72.
Sentinel lymph node biopsy analysis
Sentinel lymph node is the first one in which tu-
mor cells from primary tumor migrate. If this node is 
without malignant cells, the lymphadenectomy can be 
avoided. This concept is well established in some tu-
mors, such as breast and penile cancer. Different trac-
ers are used for marking the sentinel lymph node in-
cluding indocyanine green, 99mTc-NC and SPION 
(superparamagnetic iron oxide nanoparticles)73. A sys-
tematic review of 19 studies about diagnostic accuracy 
of sentinel lymph node biopsy (SNB) in PCa showed 
median sensitivity of 95.2%, specificity of 100%, posi-
tive predictive value of 100%, negative predictive value 
of 98% and false negative rate of 4.8%73. This is almost 
comparable with ePLND and some authors recom-
mended removal of only sentinel lymph nodes in low- 
and intermediate-risk groups because this(ese) node(s) 
are often the only tumor-bearing nodes74,75. With this 
procedure the staging accuracy is maintained without 
possible surgical complications of ePLND. Compari-
son of ePLND and SNB showed that one in 20 pa-
tients who underwent ePLND has positive lymph 
nodes outside extended lymphadenectomy border be-
cause the lymphatic drainage for the prostate gland is 
very variable and complex73. Combined ePLND with 
SNB provided better nodal staging for about 5%. The 
possible oncological outcome of this finding is still un-
known. Some authors advocate performing combined 
ePLND with SNB in high-risk group patients73. SNB 
is a promising technique, but due to heterogeneity of 
different techniques it is still considered experimental 
in EAU guidelines15.
Management of prostate cancer patients  
with positive lymph nodes
Generally, the presence of malignant cells in lymph 
nodes after radical prostatectomy has a poor prognos-
tic sign. Positive lymph nodes are connected with an 
increased long-term risk of death (20-42%)76,77. Cur-
rently, the modality and starting of therapy are differ-
ent between institutions but therapeutic strategy in-
cludes observation until biochemical recurrence, adju-
vant (mostly lifelong) androgen deprivation therapy 
(ADT) and combination of ADT and external beam 
radiotherapy (EBRT)78-82.
The outcome of 369 men with lymph node-posi-
tive PCa after radical prostatectomy followed only by 
observation showed that 5- and 10-years overall sur-
vival was 91% and 60%. The predicted 5- and 10-year 
cancer-specific survival was 94% and 72%. 28% of pa-
tients remain free of biochemical recurrence and 65% 
of them remain free of distant metastasis up to 10 
years of follow-up. Most recurrences occurred within 
the first five years. If the patients were recurrence free 
after first five years, the probability of remaining free 
from recurrence after 10 years is 81%. Based on this 
observation, lymphadenectomy could be potentially 
curative in some patients, but 2/3 will need further 
therapy and in one third of patients prostate cancer 
leads to death79. This suggest that patients with posi-
tive lymph nodes are a heterogenous group with dif-
ferent outcomes, which mainly depends on Gleason 
score (7 or more), the number of lymph nodes involved 
(3 or more), adjuvant radiotherapy and positive surgi-
cal margins45,79. According to the previously mentioned 
variables, patients with LNI can be stratified in low-, 
intermediate- and high-risk group with 20-year can-
cer specific mortality rates of 19.1% vs 34% vs 46% 
(Table 3)45. For PCa patients with LNI as a whole, the 
20-year rate of biochemical recurrence, metastasis, 
Fig. 5. Microscopic photography of pelvic lymph node 
metastasis. The lymph node is infiltrated with prostate 
adenocarcinoma, HE 40x (from archives of the 
Department of Pathology, University Hospital Rijeka).
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cancer-specific mortality and overall mortality were 
69%, 36%, 31% and 70%45.
The Eastern Cooperative Oncology Group random-
ized clinical trial (ECOG 3886) compared immediate 
hormonal therapy and observation in 98 PCa patients 
with positive lymph nodes after radical prostatectomy78. 
After the median follow-up of 7 years survival was sig-
nificantly higher in the men who received ADT. The 
overall survival at 7 years was 85.1 % (ADT group) and 
64.7% (observation group). Prostate cancer specific sur-
vival was 93.6% (ADT group) and 68% (observation 
group). At the last follow-up only 16% of patients in 
observation group were without recurrence (defined as 
detection of local or disseminated disease) compared to 
43% in ADT group. Authors concluded that immediate 
ADT improves survival and reduces the risk of recur-
rence in PCa patients with LNI78.
Da Pozzo et al. compared using of ADT versus 
ADT+EBRT and showed a beneficial impact on sur-
vival in combination group, especially in men with no 
more than two positive nodes, non-organ-confined 
and intermediate- to high-grade disease81.
A retrospective study of 577 patients from Surveil-
lance, Epidemiology and End Results (SEER)-Medi-
care data showed no significant difference between 
patients with LNM treated with adjuvant ADT+EBRT 
and adjuvant ADT alone83.
The most recent study retrospectively analyzed data 
of 1388 patients with LNI after radical prostatectomy 
in three tertiary oncological centers82. 28% of patients 
were observed, 49% received lifelong adjuvant ADT 
and 23% received adjuvant EBRT and ADT. Observa-
tion consisted of no treatment until biochemical recur-
rence (defined as two consecutive PSA≥ 0.1-0,4 ng/ml 
depending of institution) at which point patients 
started with therapy. Adjuvant radiotherapy included 
local radiation of prostate and seminal vesicle bed and 
pelvic lymph node areas with a median dose of 68 Gy. 
Adjuvant ADT included surgical or chemical castra-
tion. These types of therapy were usually lifelong. Most 
of the patients had pT3b stage, Gleason 7 and more 
and most of them had one or two positive lymph 
nodes. When combined with EBRT, the median dura-
tion of ADT was 5.9 years. Combination therapy was 
associated with better overall and cancer-specific sur-
vival compared to other methods. Ten-year mortality 
risk was different between ADT+EBRT, ADT alone 
and observation group and range from 5% in low-risk 
patients to 40% in high-risk patients. In concordance 
with these studies, EAU guidelines recommended 
combined adjuvant ADT and EBRT in lymph node-
positive PCa patients after radical prostatectomy15.
Modern studies showed that patients with LNI af-
ter radical prostatectomy could benefit from a multi-
modal approach using maximal local eradication of the 
disease (radical prostatectomy + extended pelvic 
lymphadenectomy + adjuvant radiotherapy)15,79,82. Pre-
viously, patients with LNI were considered as patients 
with systematic disease and were not considered for 
further curative treatment.
The optimal timing of adjuvant EBRT and adju-
vant ADT it still a matter of debate. Messing showed 
that immediate treatment (ADT) after radical prosta-
tectomy improves survival of patients with positive 
lymph nodes78. Because of a long natural history of 
prostate cancer, the influence of adjuvant therapy on 
the quality of life of these patients must be considered. 
It is well known that long-term ADT is connected 
with increased cardiovascular and metabolic effects 
which increase morbidity and mortality of these pa-
tients84. Also, EBRT has possible negative impact on 
voiding, bowel function and erectile function85. To pre-
vent these negative effects some authors suggested 
starting the therapy after biochemical recurrence (ear-
ly salvage radiation therapy) but this concept must be 
tested by using randomized trials86.
Other prognostic factors
LNI is not the only prognostic factor in patients 
undergoing radical prostatectomy. Other prognostic 
Table 3. Stratification of prostate cancer patients  
with positive lymph nodes into different risk groups  
of cancer specific mortality 
Parameters and risk score for different risk groups  
of cancer specific mortality
Parameters Points Risk group Point Range
Gleason 7
Gleason 8-10
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variables include seminal vesicle invasion, extracapsu-
lar extension and positive surgical margins and all are 
associated with a poor prognosis15. The incidence of 
these factors in patients treated with RP is more fre-
quent than LNI. Also, patients with LNI are more 
likely to have simultaneously seminal vesicle invasion 
(up to 67,3%), extracapsular extension (up to 97%) and 
positive surgical margin (up to 64.3%)87. So, even when 
all positive lymph nodes were removed during ePLND 
it was unlikely that all cancer sites are removed in pa-
tients with positive surgical margins, for example.
Conclusion
Pelvic lymphadenectomy (PLND) represents an 
essential staging procedure for patients undergoing 
radical prostatectomy and it is performed in selected 
patients. A very important role of ePLN is that defin-
ing lymph nodes as positive or negative can determine 
the risk of progression. In subset of patients ePLND 
can also be the curative procedure with removal of all 
involved lymph nodes. In other patients, especially in 
the intermediate and high-risk group, multimodal ap-
proach using adjuvant radiotherapy and hormonal 
therapy has a potentially positive effect on their overall 
and cancer-specific survival.
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Sažetak
ULOGA LIMFADENEKTOMIJE U BOLESNIKA S KARCINOMOM PROSTATE
D. Markić, R. Oguić, K. Krpina, I. Vukelić, G. Đorđević, I. Žuža i J. Španjol
Karcinom prostate je jedan od značajnijih zdravstvenih problema muškaraca u razvijenom dijelu svijeta. U bolesnika s 
dijagnosticiranim karcinomom prostate neophodno je učiniti prijeoperacijsko stupnjevanje bolesti. Zahvaćenost limfnih čvo-
rova se standardno određuje uz pomoć slikovnih metoda (CT i/ili/ MR) iako postoje i novije metode (PET/CT, PSMA 
PET/CT). U određenog broja bolesnika prilikom radikalne prostatektomije treba učiniti i zdjeličnu limfadenektomiju. Od-
luka o potrebi za zdjeličnom limfadenektomijom se donosi na osnovu svrstavanja bolesnika u umjerenu odnosno grupu viso-
koga rizika i ako je vjerojatnost za zahvaćenost limfnih čvorova povećana. Najčešće danas korišteni nomogrami za prijeope-
racijsku procjenu zahvaćenosti limfnih čvorova su Briganti i MSKCC nomogram te Partin-ove tablice. Zdjelična limfade-
nektomija može obuhvaćati različite skupine limfnih čvorova ali se preporuča učiniti proširenu zdjeličnu limfadenektomiju. 
U 1-20% bolesnika nalaze se pozitivni limfni čvorovi. Iako zdjelična limfadenektomija ima prvenstveno dijagnostički i pro-
gnostički značaj, u manjeg broja bolesnika s pozitivnim limfnim čvorovima može biti i definitivna terapijska metoda. U 
ostalih bolesnika s pozitivnim limfnim čvorovima adjuvantna terapija (radioterapija i androgen deprivacijska terapija) može 
biti od terapijskog značaja.
Ključne riječi: Karcinom prostate; Radikalna prostatektomija; Zdjelična limfadenektomija; Radioterapija
